CHU Bordeaux
Bordeaux, France
NCT Number: NCT04354909
The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Bordeaux, France
Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets.
This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms.
Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
levels of s-CD95-L (ELISA test)
Time frame: Baseline
levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients
Time frame: Baseline, Month 3
Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination)
Time frame: Baseline, Month 3
Th17 dosage
Time frame: Baseline, Month 3
polynuclear neutrophils levels (Flow cytometry)
University Hospital, Bordeaux
Other
Acronym: UVE-FAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.